Shares of Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) traded up 98.2% during trading on Thursday . The company traded as high as $0.04 and last traded at $0.04, 1,192 shares traded hands during trading. A decline of 96% from the average session volume of 31,620 shares. The stock had previously closed at $0.02.
The business has a fifty day moving average price of $0.35.
Mabvax Therapeutics Company Profile (NASDAQ:MBVX)
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Further Reading: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Mabvax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mabvax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.